These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 21135089)

  • 21. Once-daily i.v. BU-based conditioning regimen before allogeneic hematopoietic SCT: a study of influence of GST gene polymorphisms on BU pharmacokinetics and clinical outcomes in Chinese patients.
    Yin J; Xiao Y; Zheng H; Zhang YC
    Bone Marrow Transplant; 2015 May; 50(5):696-705. PubMed ID: 25730183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of glutathione S-transferase gene polymorphisms on busulfan pharmacokinetics and outcome of hematopoietic stem-cell transplantation in thalassemia pediatric patients.
    Ansari M; Huezo-Diaz P; Rezgui MA; Marktel S; Duval M; Bittencourt H; Cappelli B; Krajinovic M
    Bone Marrow Transplant; 2016 Mar; 51(3):377-83. PubMed ID: 26691424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Variation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipients.
    McCune JS; Baker KS; Blough DK; Gamis A; Bemer MJ; Kelton-Rehkopf MC; Winter L; Barrett JS
    J Clin Pharmacol; 2013 Mar; 53(3):264-75. PubMed ID: 23444282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of genetic polymorphisms in genes encoding GST isoenzymes on BU pharmacokinetics in adult patients undergoing hematopoietic SCT.
    ten Brink MH; Wessels JA; den Hartigh J; van der Straaten T; von dem Borne PA; Guchelaar HJ; Zwaveling J
    Bone Marrow Transplant; 2012 Feb; 47(2):190-5. PubMed ID: 21441958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exploratory analysis of 1936 SNPs in ADME genes for association with busulfan clearance in adult hematopoietic stem cell recipients.
    Ten Brink MH; Swen JJ; Böhringer S; Wessels JA; van der Straaten T; Marijt EW; von dem Borne PA; Zwaveling J; Guchelaar HJ
    Pharmacogenet Genomics; 2013 Dec; 23(12):675-83. PubMed ID: 24192531
    [TBL] [Abstract][Full Text] [Related]  

  • 26. GSTA1 Genetic Variants and Conditioning Regimen: Missing Key Factors in Dosing Guidelines of Busulfan in Pediatric Hematopoietic Stem Cell Transplantation.
    Nava T; Rezgui MA; Uppugunduri CRS; Curtis PH; Théoret Y; Duval M; Daudt LE; Ansari M; Krajinovic M; Bittencourt H
    Biol Blood Marrow Transplant; 2017 Nov; 23(11):1918-1924. PubMed ID: 28807770
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of
    Michaud V; Tran M; Pronovost B; Bouchard P; Bilodeau S; Alain K; Vadnais B; Franco M; Bélanger F; Turgeon J
    Pharmaceutics; 2019 Sep; 11(9):. PubMed ID: 31480560
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glutathione S-transferase gene variations influence BU pharmacokinetics and outcome of hematopoietic SCT in pediatric patients.
    Ansari M; Rezgui MA; Théoret Y; Uppugunduri CR; Mezziani S; Vachon MF; Desjean C; Rousseau J; Labuda M; Przybyla C; Duval M; Champagne M; Peters C; Bittencourt H; Krajinovic M;
    Bone Marrow Transplant; 2013 Jul; 48(7):939-46. PubMed ID: 23292236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glutathione S-transferase A1 polymorphisms and acute graft-vs.-host disease in HLA-matched sibling allogeneic hematopoietic stem cell transplantation.
    Kim I; Keam B; Lee KH; Kim JH; Oh SY; Ra EK; Yoon SS; Park SS; Kim CS; Park S; Hong YC; Kim BK
    Clin Transplant; 2007; 21(2):207-13. PubMed ID: 17425746
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy.
    Lindley C; Shea T; McCune J; Shord S; Decker J; Harvey D; Petros WP; Garbriel D; Serody J; Kirby S; Wiley J
    Anticancer Drugs; 2004 Jun; 15(5):453-9. PubMed ID: 15166618
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacometabonomic Prediction of Busulfan Clearance in Hematopoetic Cell Transplant Recipients.
    Navarro SL; Randolph TW; Shireman LM; Raftery D; McCune JS
    J Proteome Res; 2016 Aug; 15(8):2802-11. PubMed ID: 27350098
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glutathione Transferase Gene Variants Influence Busulfan Pharmacokinetics and Outcome After Myeloablative Conditioning.
    Bremer S; Fløisand Y; Brinch L; Gedde-Dahl T; Bergan S
    Ther Drug Monit; 2015 Aug; 37(4):493-500. PubMed ID: 25565670
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glutathione transferase-A2 S112T polymorphism predicts survival, transplant-related mortality, busulfan and bilirubin blood levels after allogeneic stem cell transplantation.
    Bonifazi F; Storci G; Bandini G; Marasco E; Dan E; Zani E; Albani F; Bertoni S; Bontadini A; De Carolis S; Sapienza MR; Rizzi S; Motta MR; Ferioli M; Garagnani P; Cavo M; Mantovani V; Bonafè M
    Haematologica; 2014 Jan; 99(1):172-9. PubMed ID: 24056816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation.
    Srivastava A; Poonkuzhali B; Shaji RV; George B; Mathews V; Chandy M; Krishnamoorthy R
    Blood; 2004 Sep; 104(5):1574-7. PubMed ID: 15142875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use.
    Long-Boyle JR; Savic R; Yan S; Bartelink I; Musick L; French D; Law J; Horn B; Cowan MJ; Dvorak CC
    Ther Drug Monit; 2015 Apr; 37(2):236-45. PubMed ID: 25162216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic and pharmacogenetic analysis of oral busulfan in stem cell transplantation: prediction of poor drug metabolism to prevent drug toxicity.
    Krivoy N; Zuckerman T; Elkin H; Froymovich L; Rowe JM; Efrati E
    Curr Drug Saf; 2012 Jul; 7(3):211-7. PubMed ID: 22950985
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study.
    Ansari M; Curtis PH; Uppugunduri CRS; Rezgui MA; Nava T; Mlakar V; Lesne L; Théoret Y; Chalandon Y; Dupuis LL; Schechter T; Bartelink IH; Boelens JJ; Bredius R; Dalle JH; Azarnoush S; Sedlacek P; Lewis V; Champagne M; Peters C; Bittencourt H; Krajinovic M
    Oncotarget; 2017 Oct; 8(53):90852-90867. PubMed ID: 29207608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predicting the presence and mechanism of busulfan drug-drug interactions in hematopoietic stem cell transplantation using pharmacokinetic interaction network-based molecular structure similarity and network pharmacology.
    Hao C; Ma X; Wang L; Zhang W; Hu J; Huang J; Yang W
    Eur J Clin Pharmacol; 2021 Apr; 77(4):595-605. PubMed ID: 33179758
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population pharmacokinetics of busulfan in Saudi pediatric patients undergoing hematopoietic stem cell transplantation.
    Alsultan A; Albassam AA; Alturki A; Alsultan A; Essa M; Almuzzaini B; Alfadhel S
    Int J Clin Pharm; 2020 Apr; 42(2):703-712. PubMed ID: 32140913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation.
    Schuler US; Ehrsam M; Schneider A; Schmidt H; Deeg J; Ehninger G
    Bone Marrow Transplant; 1998 Aug; 22(3):241-4. PubMed ID: 9720736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.